Amedisys had its Relative Strength (RS) Rating upgraded from 62 to 71 Monday — a welcome improvement, but still shy of the 80 or higher score you look for.
This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
History shows that the best stocks tend to have an 80 or better RS Rating as they launch their biggest climbs. See if Amedisys can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Amedisys is trying to complete a consolidation with a 98.95 entry. See if the stock can break out in heavy trading.
The company showed 2% EPS growth last quarter, while sales growth came in at 5%. The company is expected to report its latest results on or around Apr. 23.
The company earns the No. 8 rank among its peers in the Medical-Outpatient/Home Care industry group. Encompass Health, AdaptHealth and Fresenius Medical Care are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
